Soma Carisoprodol News Blog

In an attempt to determine the mechanism of action of carisoprodol (Soma) in the treatment of low back pain, a double blind study was carried out comparing its effectiveness to that of a sedative control, butabarbital (a sedative), and a placebo in the treatment of 48 laborers with acute lumbar pain. The results of the study have shown that carisoprodol is significantly more effective than butabarbital or placebo in providing both subjective pain relief and objective improvements in range of motion when evaluated by finger to floor testing (4). The results of the study suggests that effects of carisoprodol are not due solely to sedative action, but are also related to its muscle relaxant activity.

In a double-blind study carisoprodol was found to be superior to diazepam in the treatment of patients with at least moderately severe low back pain and spasm of no longer than seven days duration.

The first RCT (80 people) found that carisoprodol significantly increased overall improvement compared with diazepam but found no significant difference in pain at 7 days (improvement rated as very good or excellent; 70% with carisoprodol v 45% with diazepam; pain on 100 mm visual analogue scale: 58 mm with carisoprodol v 48 mm with diazepam; P values not reported in the review)

Carisoprodol was more effective than diazepam in overall relief of acute LBP (70% vs. 45%)

In a trial of cyclobenzaprine versus carisoprodol in patients with acute back pain and spasms there were no significant differences for pain, muscle stiffness, activity impairment, sleep impairment, tension, or relief scores compared to baseline. In this head-to-head trial dry mouth was more frequent with cyclobenzaprine (38% vs. 10%) and dizziness less frequent (8% vs. 26%). Withdrawal rates due to adverse events were equal (8%) (3).